MCL1 and neoplasm: In contrast, by combining AZD8055 with platelet-sparing BCL-XL degrader DT2216, we achieved tumor-selective targeting of both MCL-1 and BCL-XL, respectively, without significant on-target toxicity both in cell culture and in mice.